74 related articles for article (PubMed ID: 9474178)
1. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.
Lodding P; Aus G; Bergdahl S; Frösing R; Lilja H; Pihl CG; Hugosson J
J Urol; 1998 Mar; 159(3):899-903. PubMed ID: 9474178
[TBL] [Abstract][Full Text] [Related]
2. A comparative performance analysis of total PSA, percentage free PSA, PSA velocity, and PSA density versus the detection of primary circulating prostate cells in predicting initial prostate biopsy findings in Chilean men.
Murray NP; Reyes E; Orellana N; Fuentealba C; Dueñas R
Biomed Res Int; 2014; 2014():676572. PubMed ID: 25101294
[TBL] [Abstract][Full Text] [Related]
3. Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial.
Yim K; Ma C; Carlsson S; Lilja H; Mucci L; Penney K; Kibel AS; Eggener S; Preston MA
J Urol; 2023 Oct; 210(4):630-638. PubMed ID: 37384841
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of prostate cancers found in specimens removed by radical cystoprostatectomy for bladder cancer and their relationship with serum prostate-specific antigen level.
Nakagawa T; Kanai Y; Komiyama M; Fujimoto H; Kakizoe T
Cancer Sci; 2009 Oct; 100(10):1880-4. PubMed ID: 19659608
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of screen detected prostate cancer in West Africans: implications for racial disparity of prostate cancer.
Hsing AW; Yeboah E; Biritwum R; Tettey Y; De Marzo AM; Adjei A; Netto GJ; Yu K; Li Y; Chokkalingam AP; Chu LW; Chia D; Partin A; Thompson IM; Quraishi SM; Niwa S; Tarone R; Hoover RN
J Urol; 2014 Sep; 192(3):730-5. PubMed ID: 24747091
[TBL] [Abstract][Full Text] [Related]
6. Low free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trial.
Bayar G; Şirin H; Aydın M; Özağarı A; Tanrıverdi O; Kadıhasanoğlu M; Kendirci M
Turk J Urol; 2017 Sep; 43(3):289-296. PubMed ID: 28861300
[TBL] [Abstract][Full Text] [Related]
7. Screening for Prostate Cancer.
Carlsson SV; Vickers AJ
Med Clin North Am; 2020 Nov; 104(6):1051-1062. PubMed ID: 33099450
[TBL] [Abstract][Full Text] [Related]
8. Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study.
Eldred-Evans D; Winkler M; Klimowska-Nassar N; Burak P; Connor MJ; Fiorentino F; Day E; Price D; Gammon M; Tam H; Sokhi H; Padhani AR; Ahmed HU
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):531-537. PubMed ID: 37002379
[TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer Screening in Jamaica: Results of the Largest National Screening Clinic.
Morrison BF; Aiken W; Mayhew R; Gordon Y; Reid M
J Cancer Epidemiol; 2016; 2016():2606805. PubMed ID: 27034668
[TBL] [Abstract][Full Text] [Related]
10. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
11. How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer?
Serefoglu EC; Altinova S; Ugras NS; Akincioglu E; Asil E; Balbay MD
Can Urol Assoc J; 2013; 7(5-6):E293-8. PubMed ID: 22398204
[TBL] [Abstract][Full Text] [Related]
12. Discovery and validation of urinary biomarkers for prostate cancer.
Theodorescu D; Schiffer E; Bauer HW; Douwes F; Eichhorn F; Polley R; Schmidt T; Schöfer W; Zürbig P; Good DM; Coon JJ; Mischak H
Proteomics Clin Appl; 2008 Mar; 2(4):556-570. PubMed ID: 19759844
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and outcome of prostate cancer with PSA <4 ng/ml at diagnosis: a population-based study.
Bonet M; Merglen A; Fioretta G; Rapiti E; Neyroud-Caspar I; Zanetti R; Miralbell R; Bouchardy C
Clin Transl Oncol; 2009 May; 11(5):312-7. PubMed ID: 19451064
[TBL] [Abstract][Full Text] [Related]
14. Retrospective descriptive analysis of the physiological kinetics of prostate-specific antigen in men older than 75 years.
Sighinolfi MC; Micali S; De Stefani S; Cicero A; Cianci F; Giacometti M; Bianchi G
Asian J Androl; 2009 Jul; 11(4):493-7. PubMed ID: 19448643
[TBL] [Abstract][Full Text] [Related]
15. Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm.
Metzger J; Luppa PB; Good DM; Mischak H
Crit Rev Clin Lab Sci; 2009; 46(3):129-52. PubMed ID: 19404829
[TBL] [Abstract][Full Text] [Related]
16. A questionnaire survey of patient preparation and techniques for prostate biopsy among urologists in the Kyushu and Okinawa regions of Japan.
Noguchi M; Matsuoka K; Koga H; Kanetake H; Nakagawa M; Naito S
Int J Clin Oncol; 2006 Oct; 11(5):390-5. PubMed ID: 17058137
[TBL] [Abstract][Full Text] [Related]
17. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer.
Shariat SF; Canto EI; Kattan MW; Slawin KM
Rev Urol; 2004; 6(2):58-72. PubMed ID: 16985579
[TBL] [Abstract][Full Text] [Related]
18. [Validity of digital rectal examination in the era of prostate specific antigen].
Alonso-Sandoica E; Jara-Rascón J; Martínez-Salamanca JI; Hernández-Fernández C
Aten Primaria; 2006 Jan; 37(1):9-14. PubMed ID: 16545295
[TBL] [Abstract][Full Text] [Related]
19. Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
Bruun L; Becker C; Hugosson J; Lilja H; Christensson A
Prostate; 2005 Nov; 65(3):216-21. PubMed ID: 15948137
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
Haese A; Graefen M; Huland H; Lilja H
Curr Urol Rep; 2004 Jun; 5(3):231-40. PubMed ID: 15161573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
